Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

BACKGROUND: β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and Drug Administration-approved method to support clinical diagnosis of Alzheimer’s disease (AD). However, numerous research studies support the use of cerebrospinal fluid (CSF) biomarkers, as a cost-ef...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Alzheimers Res Ther
Autors principals: Doecke, James D., Ward, Larry, Burnham, Samantha C., Villemagne, Victor L., Li, Qiao-Xin, Collins, Steven, Fowler, Christopher J., Manuilova, Ekaterina, Widmann, Monika, Rainey-Smith, Stephanie R., Martins, Ralph N., Masters, Colin L.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7110644/
https://ncbi.nlm.nih.gov/pubmed/32234072
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-020-00595-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars